Pharma Tech Outlook: Pharma Tech Magazine

Karma Oncology: Unravel the Complexities in Clinical Trials

Top 5 CROs in UK - 2019


Clinical research marks a pivotal point in the drug development process as it assesses the safety and effectiveness of medications, devices, and treatment regimens planned for humans. As the CRO space continues to experience radical changes, there is no doubt that clinical trials are continually becoming more complex. Traditionally, CROs were generally only considered for clinical trials and lab services. These days the market has evolved to cover data and analytics for trial insights and design, drug development planning, medical affairs, and regulatory consulting. The need to make data-driven decisions and elevate the quality of trials by leveraging technology is already making its presence felt, and CROs are becoming part of the solution.

As the pharmaceutical industry embraces new technologies and innovations, including electronic record keeping, the volume of information collected before, during, and after clinical trials, continues to grow. Similar to the adoption of electronic data capture (EDC) systems, which initially started slow and now is the norm, it could be expected that the same will occur with data quality oversight (DQO) once monitoring efforts are centralized. The application of advanced technology and analytics is creating a new pool of opportunities for improving trial performance by bringing forth cutting-edge approaches for trial designs, site selections, and patient recruitments. For instance, virtual clinical trials can enable CROs to be more effective and patient-centric as it enables them to create a more personalized approach that reduces the burden on patients. Technologies like Artificial intelligence and machine learning are also bringing in increased efficiencies to the statistical analysis and programming of clinical data along with the increasing costs in drug development.

Growth has also come from rising demand for safety and pharmacovigilance, clinical trial feasibility, and protocol optimisation. Today, CROs are navigating into trials through deploying evidence-driven design capabilities that can shorten study timelines, reduce protocol amendments, and subsequently bolster the patience recruitment process with more precise targeting. Many major corporations are outsourcing clinical trials, drug discovery, drug development, outsourcing, and various other services to CROs as a result of the increasing size, complexity, duration, and costs.

Understanding the changing times, Pharma Tech Outlook has compiled a list of Top 10 CROs in UK to guide companies associated with the pharmaceutical sector in harnessing the power of technology to leverage digital capabilities in critical functions including research and manufacturing of the therapeutic drugs and medical devices, while simultaneously broaden treatment options and help improve patient health. In this edition, we are glad to feature various CROs that are at the forefront of revolutionizing the pharmaceutical space through their groundbreaking clinical research solutions and services. We hope this issue of the Pharma Tech Outlook helps you build the partnership you and your firm needs to foster a technologically-driven pharmaceutical landscape.

We present to you Pharma Tech Outlooks’ “Top 10 CROs in UK – 2019.”

    Top CROs in UK

  • A focused oncology clinical development company, Karma Oncology provides pharmaceutical and biotechnology firms with bespoke services including, but not limited to, clinical development planning and full-service clinical trial execution. Founded in 2012 by Dr. Karen J. Williams, Karma Oncology specialises in the preparation of clinical development plans along with the design, set-up, monitoring, management, and reporting of oncology clinical trials. Taking into consideration various factors, such as tumour types, possible combination therapies, as well as tactical country and site selection, regulatory strategy, and an organisation’s ultimate aim (e.g. early exit, pharma-partnering, or autonomous full development), the team at Karma Oncology can map out the details of the phase I/II, II and III clinical trials required to ensure success

  • A leading preclinical CRO for cross-species and cross-therapeutic area translational pharmacology

  • Apex Molecular

    Apex Molecular

    Apex Molecular is a synthetic chemistry company that offers specialist synthesis services for the pharmaceutical, biotechnology (life sciences), and applied chemical sectors. They have customers starting from innovative drug discovery, biotech, agritech to advanced materials companies. Apex also offers fast, reliable, cost-effective delivery of laboratory scale chemistry synthesis services for the life sciences and to extensive chemical sectors. They can also undertake projects across the pre-clinical early development phase, which also includes multi-FTE collaborations. The company works closely with its clients to integrate their chemistry services into their organizations to extend their abilities and speed up the development of their project pipelines

  • Clintec


    Clintec is an innovative, medium-sized global Contract Research Organization that offers full and functional service support globally to the pharmaceutical, biotechnology, and medical device industries. The company have the headquarter in the UK and have grown our clinical research business organically over the past 20 years. Clintec merges the agility and flexibility of the smaller CROs with the global coverage associated with large CROs. Moreover, the company delivers global projects with speed, efficiency, and cost-effectiveness. They put their effort into meeting the necessities of their clients’ by being proactive and have created an environment that cultivates this approach with their teams

  • Oxon


    OXON is a full-service scientific Contract Research Organization (CRO). The company specializes in real-world data for pre- and post-approval products via strategic, scientific, and operational solutions to the biopharmaceutical and medical device industries. The company focuses in real-world data in the areas of Safety, HEOR/market access, Drug development and Marketing with the help of multi-country field, chart review and database epidemiological studies, patient registries, risk management, PASS, and risk minimization studies, quantitative benefit-risk analysis for CTD / PBRER, and many more. OXON is also an ENCePP center of the EMA, and here they are leading an initiative on data integration with EMA regulators and leading academic pharmacoepidemiologists